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Abstract
Background—Men with prostate cancer who undergo androgen deprivation therapy (ADT) are 
at risk for bone loss and fractures. Our objective was to determine if Medicare beneficiaries with 
prostate cancer in the state of Texas underwent DXA scans when initiating ADT.
Methods—We identified men diagnosed with prostate cancer between 2005 and 2007 in the 
Texas Cancer Registry/Medicare linked database, and who received parenteral ADT or 
orchiectomy. We identified DXA claims within 1 year before or 6 months after starting ADT. We 
examined use of bone conservation agents in the subgroup of patients enrolled in Medicare Part D. 
Multivariate logistic regression models were used to examine determinants of DXA use.
Results—The analysis included 2,290 men (2,262 parenteral ADT, 28 orchiectomy): 197 (8.6%) 
underwent DXA within 1 year before and 6 months after starting ADT. Men aged 75 years or 
older were more likely to undergo DXA than men aged 66-74 years (OR:1.5; 95%CI:1.1-2.1). 
Those living in small urban areas were less likely to undergo DXA than those in big areas (OR:
0.40; 95%CI:0.19-0.82). Of the 1,060 men enrolled in Medicare Part D, 59 (5.6%) received bone 
conservation agents when starting ADT; 134 (12.6%) either received bone conservation agents or 
underwent DXA.
Conclusions—Fewer than 1 in 10 Medicare beneficiaries with prostate cancer initiating ADT 
underwent a DXA exam. Variation in utilization was also related to residence area size. Further 
research is needed to identify whether the use of DXA in patients with prostate cancer receiving 
ADT will result in fracture prevention.
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Androgens promote growth and survival of prostate cancer cells.1 Androgen deprivation 
therapy (ADT) through surgical or medical castration is first line of therapy for metastatic 
prostate cancer, and is also sometimes used as neo-adjuvant therapy in men with localized 
disease. Although ADT improves survival rates, it has important adverse effects, including 
nonmalignant bone complications. Androgens exert antiresorptive effects on bone, directly 
by promoting osteoblastic activity, and indirectly by inhibition of osteoclastic activity via 
conversion to estradiol.2 Androgen deprivation is associated with accelerated bone loss and 
an increased risk for fractures, seen as early as 6 months after initiating therapy.3-8 
Moreover, many men with prostate cancer already have osteopenia, osteoporosis or vertebral 
fractures before starting ADT,9-12 and other risk factors for osteoporosis such as advanced 
age, smoking, alcohol intake, decreased physical activity, and reduced vitamin D intake.13-15
Men with prostate cancer who suffer osteoporotic fractures have poor prognosis and reduced 
survival.16-18 Bisphosphonates and denosumab can improve bone mineral density (BMD) 
and reduce the risk of fracture in men with prostate cancer receiving ADT.9,19-28 However, 
universal treatment with bisphosphonates in this population has not been shown to be cost-
effective, and measurement of BMD to identify patients at higher risk for fracture might be 
more efficient.29 The 2009 National Comprehensive Cancer Network (NCCN) 
recommended screening with dual-energy X-ray absorptiometry (DXA) prior to initiation of 
ADT.30 NCCN 2012 guidelines recommend using the Fracture Risk Assessment Algorithm 
(FRAX) to assess fracture risk.31,32 However, few studies have evaluated FRAX scores in 
patients with prostate cancer receiving ADT;33,34 they were primarily descriptive and did 
not include an evaluation of fracture risk with respect to subsequent fractures. Moreover, the 
FRAX algorithm does not include ADT as a specific risk factor. The precise role of BMD 
measurement in men receiving ADT has not been well established. While there is data 
suggesting that the majority of fractures in healthy men occur in men whose BMD is not in 
the defined osteoporotic range, there are also studies that show that BMD is predictive of 
fractures in men with prostate cancer.35-37
The objective of our study was to determine whether Medicare beneficiaries in the state of 
Texas, with prostate cancer and initiating ADT, underwent BMD measurement with DXA.
METHODS
The institutional review boards at The University of Texas M. D. Anderson Cancer Center 
and the Texas Department of State Health Services approved this study, as did the privacy 
review board of the Centers for Medicare and Medicaid Services.
We used the Texas Cancer Registry (TCR)–Medicare database from the Comparative 
Effectiveness Research Consortium in Texas (CERCIT) that links two large population-
based sources of data: TCR and Medicare claims collected by the Centers for Medicare and 
Medicaid Services. The TCR is a statewide population-based registry, the fourth largest in 
the United States. Approximately 98% of all people aged 65 or older in the TCR are 
matched with data from Medicare claims. Medicare is a federally-funded national social 
program which provides health insurance for all persons aged 65 years and older who have 
been legal residents in the United States for at least 5 years. The Texas Medicare claims 
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database contains claims for healthcare provided in Texas under hospital services (Part A), 
supplemental insurance (Part B) and since 2006, prescription drugs (Part D). Medicare Part 
A and Part B claims were available for this study from 2000 to 2009, and Medicare Part D 
claims from 2007 to 2008. Additional participation in the state buy-in program, a surrogate 
for low socioeconomic status, was defined as receiving at least one month of coverage.
We identified all men aged 66 years or older with histologically diagnosed prostate cancer 
between 2005 and 2007 (first documented primary cancer) and residing in Texas at the time 
of diagnosis. Cohort selection criteria included:
i. Claim for orchiectomy or initial parenteral ADT between 2005-2008. Bilateral 
orchiectomy was identified in Part A using the International Classification of 
Diseases 9 (ICD-9) Current Procedural Terminology (CPT) codes 62.4, 62.41, and 
62.42. J codes were used to identify the initial Part B claim for parenteral ADT.
ii. Alive for at least 1 year after diagnosis. We assumed that the risk-benefit ratio of 
osteoporosis screening might not be perceived favorable in patients with limited 
life expectancy, significant changes in BMD are generally observed only after 1 to 
2 year intervals.38
iii. Enrolled in Medicare Part A and Part B for at least 12 months before and 6 months 
after initiation of ADT. Participation in Medicare for this period of time was 
necessary to adequately evaluate use of BMD screening with DXA. Bone mineral 
density is not expected to change in less than 1 year; therefore, we assumed that if 
patients underwent DXA in the year before starting ADT, their healthcare providers 
may not have required a new test. We also allowed up to 6 months of follow-up 
after initiation of ADT for the patient to undergo DXA. We excluded patients 
enrolled in an additional health plan other than Medicare (health maintenance 
organization) because we had no access to data claimed under a different plan.
Claims for central DXA exams were captured in Part B claims with CPT code 76075 before 
January 1, 2007, and 77080 after January 1, 2007.
Demographic data in the TCR included age, sex, and ethnicity. Disease stage was 
categorized as in situ, localized, regional, distant, or unknown. The population density of the 
patient's area of residence (census tract level) was classified as big metropolitan (population 
≥1,000,000), metropolitan (metropolitan areas with a population of <1,000,000), urban 
(population of ≥20,000, non-metropolitan), small urban (population 2,500-19,999), or rural 
(population of <2,500).
Socioeconomic status variables were not available at the patient level, so a surrogate value 
was obtained from the 2000 U.S. Census data based on the median for the patients’ census 
tract as recorded in the TCR at the time of diagnosis including: education level, measured as 
the percentage of persons aged 25 years or older in the census tract with a high school 
education only, and median income.
A subgroup analysis was performed for patients who were also enrolled in Medicare Part D 
drug plans (2007 or 2008) to examine the use of bone conserving agents, many of which are 
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administered orally. We used J codes in Part B claims to identify intravenous 
bisphosphonates (ibandronate, pamidronate, and zoledronic acid) and generic names to 
identify oral bisphosphonates (alendronate, risedronate, and ibandronate), calcitonin, and 
teriparatide in Part D. We assumed that in some instances, healthcare providers might not 
have requested DXA because patients were already receiving bone conservation agents, or 
that they may have prescribed these agents without requesting DXA.
Statistical analysis
Our outcome variable was a DXA claim in the period of time ranging from 1 year before to 
6 months after initiation of ADT. We compared demographic information, cancer stage, and 
surrogate socioeconomic data between patients who underwent DXA those who did not. A 
multivariate logistic regression model was used to estimate the likelihood of DXA after 
controlling age, ethnicity, stage, size of area of residence and socioeconomic variables.
During the period of the study, DXA was an allowed reimbursable claim every 23 months, 
or more often if medical necessity could be demonstrated. However, claims might have been 
denied. Curtis et al found that 2-43% of repeat DXA procedures performed within less than 
23 months were denied, depending on the Medicare carrier.39 We therefore conducted a 
sensitivity analysis, using a window of 2 years before initiation of ADT instead of 1 year, to 
adjust for the potential effect of Medicare denials.
We examined separately patients who did not undergo DXA during the year before starting 
ADT (excluding the month immediately prior to starting ADT) to determine which factors 
were associated with undergoing DXA after initiation of ADT (during the month before the 
first claim for ADT or within 6 months after). We included the month before initiation of 
ADT in our definition because some patients may have undergone DXA as ADT was being 
planned, which may have occurred before the prescription was filled.
Finally, we examined the subgroup of patients who were enrolled in Medicare Part D to 
evaluate the use of bone conservation agents at the time of initiation of ADT.
Analyses were performed using Statistical Analysis Software (SAS) version 9.2 (SAS 
institute, Cary, NC).
RESULTS
We identified 12,678 men with prostate cancer diagnosed between 2005 and 2007 (Figure 
1). Of these, 2,481 initiated ADT between 2005 and 2008. After exclusions, our final cohort 
included 2,290 men. Most men (74.8%) had localized disease (Table 1). Twenty-eight men 
(1.2%) underwent orchiectomy and 2,262 (98.8%) parenteral ADT.
Of the 2,290 men in the cohort, 197 (8.6%) underwent DXA within the specified 18-month 
window, 65 (2.8%) during the year before starting ADT and 135 (5.9%) during the 6 months 
after starting ADT (3 men had DXA claims both before and after starting ADT). Of the 28 
patients with orchiectomy, none underwent DXA. When we increased our time window to 
30 months (2 years before initiation of ADT and 6 months after), 2,181 men were included: 
of these, 209 (9.6%) underwent DXA, 84 (3.9%) during the 2 years before starting ADT and 
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130 (6.0%) during the 6 months after starting ADT (5 men had DXA claims both before and 
after starting ADT).
Men aged 66-74 years were less likely to undergo DXA than older men (7.0% vs 10.2%, 
p<0.007)(Table 1). The patient's area of residence was also related to DXA use; men from 
small urban areas were less likely to have undergone DXA than those in big metropolitan 
areas or rural areas. Ethnicity and tumor stage were not related to DXA use, but because so 
few men underwent DXA, the sample sizes in each category were small.
In multivariate logistic regression analysis, only age and area of residence were associated 
with DXA use after controlling for all other demographic variables, cancer stage, type of 
ADT, and enrollment in the state buy-in program (Table 2). Patients aged 75 years or older 
were 1.5 times more likely to have undergone DXA compared with those who were younger 
(aged 66-74 years). Patients living in small urban areas were significantly less likely than 
those in big metropolitan areas or in rural areas to have undergone DXA. African-American 
men were less likely to have undergone DXA than non-Hispanic white men (OR: 0.58, 95% 
CI: 0.30-1.1), although the difference did not reach statistical significance, possibly owing to 
the small number of men in each ethnic group. We examined potential interactions effects 
between independent variables. The only interaction term that was statistically significant 
was median income*state buy-in insurance, but since the latter variable was not significant 
in the final model, the interaction term was not included. The sensitivity analysis that 
included men who had undergone DXA within 2 years before starting ADT showed similar 
results for both univariate and multivariate analyses (data not shown).
The subgroup of patients who had not undergone DXA before starting ADT included 2,214 
men; of these, 153 (6.9%) underwent DXA at the time of first ADT claim (within 30 days 
before starting ADT) or within 6 months afterwards. Multivariate logistic regression showed 
similar results as for the entire cohort (data not shown).
The subgroup of men who were enrolled in Medicare Part D included 1,060 men (46% of 
the cohort), of whom 1,043 underwent parenteral ADT and 17 orchiectomy. Of these, 59 
(5.6%) received bone conservation agents within 6 months after ADT. In addition, 91 
(8.6%) underwent DXA within 1 year before or 6 months after starting ADT. Overall, 134 
men (12.6%) either received bone conservation agents after starting ADT or underwent 
DXA during the time window considered (16 men underwent both). Table 3 shows the 
results of the logistic regression analysis model. Men with distant cancer were 7.6 times 
more likely to have undergone DXA or have received bone conservation agents than patients 
with milder disease, and 82% of them received zoledronic acid. Men who underwent 
orchiectomy were less likely than those who underwent parenteral ADT to undergo DXA or 
receive bone conservation agents. Men in rural areas were 4.6 times more likely than men in 
big metropolitan areas to undergo DXA or receive bone conservation agents, primarily 
related to DXA use (19% of patients in rural areas underwent DXA compared with 8% in 
big metropolitan areas, p=0.02). Finally, we observed that significantly fewer men in the 
third quartile of census tract educational levels underwent DRX or received bone 
conservation agents compared with men in the first. No differences in other quartiles and no 
decreasing trends suggesting “dose effects” were observed.
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Our objective was to examine the use of BMD measurement with DXA in Texas Medicare 
beneficiaries with prostate cancer initiating ADT. We used liberal time windows to assess 
the appropriateness of management, assuming that DXA within a year before or 6 months 
after starting ADT could be considered adequate. Only a minority of men, fewer than 1 in 
10, and none of those who underwent orchiectomy had a DXA claim. To our knowledge, 
this is the first population-based study examining BMD screening practices in this patient 
population in the United States, identifying patients in a state registry linked to Medicare 
claims. Two smaller studies evaluated practices at single institutions. A retrospective chart 
review of 174 men with prostate cancer initiating parenteral ADT at Henry Ford Hospital in 
Detroit found that only 9% underwent DXA.34 Nelson reported better results at their 
institution where 38% of men with prostate cancer receiving ADT underwent DXA.40 We 
are only aware of two population-based studies, both in Canada. A study in British 
Columbia showed that after the British Columbia Cancer Agency published key 
recommendations in 2004 for BMD measurement in patients undergoing ADT, screening 
increased from 7.5% to 25% 41. A separate study in Ontario, showed that BMD screening in 
men with prostate cancer undergoing ADT increased between 1995 and 2008, reaching 18% 
in 2008.42 Although the authors of the study concluded that a screening rate of 18% was 
low, this rate is double what we observed in Texas. Our findings and those of others suggest 
that BMD screening in these patients is low across all geographic regions that have been 
examined. While our study did not specifically address the outcomes of screening, it is well 
known that treatment of osteoporosis prevents fractures. Patients with prostate cancer 
receiving ADT are at increased risk for fractures, and therapy with bisphosphonates or 
denosumab reduces this risk.9,19-28 Universal therapy is not a recommended approach, and 
therefore BMD screening can assist in selecting those patients who can benefit from 
therapy.29
The reasons for low rates of BMD screening are unclear. We examined whether use of bone 
conservation agents might have led to fewer screenings: conceivably, providers could 
perceive that BMD screening for patients already being treated might not be necessary. 
However, this was not the case; only 5.6% of the men in the Medicare Part D subanalysis 
were receiving bone conservation agents within 6 months after starting ADT. Furthermore, 
many of these men had advanced disease and were receiving zoledronic acid. We found that 
slightly more patients aged 75 years or older (10.2%) compared with those aged 66-74 years 
(7.0%) underwent DXA, but few other factors were found to be associated with DXA use. In 
particular, low socioeconomic status, which has been shown to be a predictor of less BMD 
screening in general (non-cancer) populations, was not associated with DXA use in our 
study.43 However, for our analysis, we did not have individual patient data and used 
surrogate data derived from median values in census tracts instead. Interestingly, patients 
living in small urban areas were less likely to undergo DXA than those residing in big 
metropolitan areas or rural areas. Patients in rural areas might seek cancer care in large cities 
and therefore receive similar interventions to those living in metropolitan areas. Ethnicity 
has been associated with BMD screening in female (non-cancer) Medicare beneficiaries 
suffering from a hip fracture, with African-American women being half as likely to undergo 
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screening as white women.44 In our study, African-American men were less likely to 
undergo testing (OR: 0.58) compared with white men, but because so few patients (5% vs 
9%) were tested, the difference was not statistically significant.
Osteoporosis screening in elderly men in general is recommended by guidelines, but 
screening rates remain very low.39 Providers may underestimate the risk of osteoporosis in 
men, and the benefits of osteoporosis screening.45,46 Healthcare related factors include 
competing demands during the patient encounter, and low reimbursement rates for DXA. 
Previous studies among non-cancer populations have shown that point-of-care clinical 
decision support systems, such as electronic reminders, education of physicians and patients, 
and incentive-driven quality benchmarks can improve rates of screening for 
osteoporosis.47,48 Implementation of these measures in settings specifically providing 
healthcare to cancer patients has not been assessed.
The precise indication of BMD measurement in men with prostate cancer undergoing ADT 
requires further consideration. In the general population, many fractures in otherwise healthy 
men occur in individuals who do not have osteoporosis as defined by DXA. Algorithms that 
include other risk factors for fracture have been proposed. FRAX can be estimated both with 
and without BMD. While its use has been reported in men receiving ADT, there is 
insufficient data to suggest that it is indeed a better determinant of fractures than DXA in 
this population (especially the non DXA algorithm). The FRAX algorithm does not 
specifically inquire about ADT as a risk factor, and inclusion under a particular category has 
not been validated.
To our knowledge, this is the first population-based study using Medicare beneficiaries to 
evaluate DXA use among men with prostate cancer undergoing ADT. Because we used 
administrative datasets, there are limitations to our findings. We were unable to determine 
whether DXA may have been requested but not performed or reimbursed in some instances 
because we only had access to claims. We did not examine healthcare provider 
characteristics because the data available to us did not have unique provider identifiers that 
could be linked to other data. We did not include patients receiving oral non-steroidal anti-
androgens because these drugs are thought to be less deleterious to bones than parenteral 
ADT or orchiectomy, and very few patients received oral agents alone. Because individual 
patient factors such as education and income were not available, we only examined 
surrogate variables. Finally, our data only evaluated patients residing in Texas, and although 
the state is ethnically diverse and has been a large recipient of national migrants, it cannot be 
generalizable to other US states or countries.
In summary, the use of DXA in Medicare beneficiaries in Texas with prostate cancer who 
were undergoing ADT was markedly low, despite the well-known deleterious effects of 
ADT on bones. Additional research is needed to evaluate the role of BMD measurement in 
patients with prostate cancer receiving ADT, and to further identify the determinants of low 
utilization and variation in this population.
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Data sources and cohort selection
Footnote: ADT: androgen deprivation therapy; HMO: health maintenance organization
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Table 1
Patient characteristics and DXA claims
All (N=2290) (% over total) DXA (n=197) (% with DXA per 
row category)
P value (DXA vs 
no DXA)
Age group, years 66 - 74 1153 (50.4%) 81 (7.0%)
0.007
*
≥75+ 1137 (49.6%) 116 (10.2%)
Ethnicity Non-Hispanic white 1691 (73.8%) 151 (8.9%) >0.20
Hispanic 345 (15.1%) 32 (9.3%)
African-American 226 (9.9%) 12 (5.3%)
Other 28 (1.2%) 2 (7.1%)
Stage Localized 1712 (74.8%) 152 (8.9%) >0.20
Regional 141 (6.2%) 13 (9.2%)
Distant 123 (5.4%) 7 (5.7%)
Unknown 314 (13.7%) 25 (8.0%)
Type of ADT Parenteral ADT 2262 (98.8%) 197 (8.7%) 0.10
Orchiectomy 28 (1.2%) 0 (0%)
Type of parenteral ADT Abarelix 2 (0.1%) 0 (0%) >0.20
Goserelin 190 (8.3%) 14 (7.4%)
Histrelin 68 (3.0%) 5 (7.4%)
Leuprolide 1842 (80.4%) 163 (8.8%)
Triptorelin 160 (7.0%) 15 (9.4%)
Area of residence Big metropolitan 1101 (48.1%) 94 (8.5%)
0.001
*
Metropolitan 659 (28.8%) 77 (11.7%)
Urban 185 (8.1%) 11 (5.9%)
Small urban 300 (13.1%) 10 (3.3%)
Rural 44 (1.9%) 5 (11.4%)
State buy-in enrollment Yes 290 (12.7%) 23 (7.9%) 0.66
No 2000 (87.3%) 174 (8.7%)
Census tract surrogate variables 
†
% with high school Q1: 2.84% - 19.63% 573 (25.0%) 58 (10.1%) >0.20
Q2: 19.64% - 26.53% 572 (25.0%) 61 (10.7%)
Q3: 26.54% - 32.65% 575 (25.1%) 42 (7.3%)
Q4: ≥32.66% 569 (24.9%) 36 (6.3%)
Median annual income Q1: $8,063 - $30,133 575 (25.1%) 52 (9.0%) >0.20
Q2: $30,134 - $37,924 570 (24.9%) 38 (6.7%)
Q3: $37,925 - $51,611 576 (25.2%) 57 (9.9%)
Q4: ≥$51,612 568 (24.8%) 50 (8.8%)




Categories represent quartiles; data was missing for one patient
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Table 2
Multivariate logistic regression model for use of DXA
Independent variables§ OR (95% CI) P value
Age, years (66 – 74) ≥75 1.5 (1.1 -2.1) 0.007
*
Race (Non-Hispanic White) Hispanic 0.87 (0.53-1.4) >0.20
African-American 0.58 (0.30-1.1) 0.10
Other 0.77 (0.18-3.4) >0.20
Stage (Localized) Regional 1.2 (0.6-2.1) >0.20
Distant 0.7 (0.3-1.6) >0.20
Unknown 0.8 (0.5-1.2) >0.20
Type of ADT (Triptorelin) Leuprolide 1.0 (0.57-1.8) >0.20
Goserelin 0.76 (0.35-1.6) >0.20
Histrelin 0.77 (0.26-2.2) >0.20
Area of residence (Big metropolitan) Metropolitan 1.3 (0.92-1.9) 0.14
Urban 0.67 (0.33-1.3) >0.20
Small urban 0.40 (0.19-0.82)
0.012
*
Rural 1.5 (0.54-4.2) >0.20
Enrolled in state buy-in (No) Yes 0.92 (0.54-1.6) >0.20
% with high school 
†
 (Q1: 2.84% - 19.63%)
Q2: 19.64% - 26.53% 1.0 (0.66-1.5) >0.20
Q3: 26.54% - 32.65% 0.74 (0.46-1.2) >0.20
Q4: 32.66%+ 0.70 (0.41-1.2) 0.18
Median annual income 
†
 (Q1: $8,063 - $30,133)
Q2: $30,134 - $37,924 0.80 (0.50-1.3) >0.20
Q3: $37,925 - $51,611 0.92 (0.58-1.5) >0.20
Q4: $51,612+ 0.71 (0.41-1.2) >0.20
2258 patients included in analysis (excluding cases with missing data and those with a claim for orchiectomy none of whom underwent DXA)




Reference category in brackets
†
Categories represent quartiles; data was missing for one patient
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Table 3
Multivariate logistic regression model for use of bone conservation agents or DXA in patients enrolled in 
Medicare Part D
Independent variables § OR (95% CI) P value
Age, years (66 – 74) ≥75 1.4 (0.91-2.0) 0.13
Ethnicity (Non-Hispanic white) Hispanic 0.96 (0.53-1.7) >0.20
African-American 1.0 (0.52-2.0) >0.20
Other 0.73 (0.16-3.3) >0.20




Unknown 1.4 (0.82-2.4) >0.20
Type of ADT (Parenteral ADT) Orchiectomy 0.12 (0.02-1.00) 0.05
*
Area of residence (Big metropolitan) Metropolitan 1.3 (0.81-2.2) >0.20
Urban 0.92 (0.41-2.1) >0.20




Enrolled in state buy-in (No) Yes 0.98 (0.58-1.6) >0.20
% with high school 
†
 (Q1: 3.87%-19.75%)
Q2: 19.76% - 26.88% 1.3 (0.75-2.2) >0.20
Q3: 26.89% - 32.89% 0.41 (0.21-0.81)
0.01
*
Q4: ≥32.90% 0.73 (0.38-1.44) >0.20
Median annual income
†
 (Q1: $8,063 - $27,937)
Q2: $27,938 - $35,426 1.5 (0.84-2.7) 0.16
Q3: $35,427 - $49,512 1.5 (0.80-2.8) >0.20
Q4: ≥$49,513 1.3 (0.65-2.6) >0.20
1059 patients included in analysis, with 134 having a claim for bone conservation agents or for a DXA exam
DXA: Dual energy x-ray absorptiometry; ADT: Androgen deprivation therapy; Q: Quartile
§
Reference category in brackets
†
Categories represent quartiles, data missing for one patient
*
statistically significant
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